Taxanes in combination with biologic agents for ovarian and breast cancers
| Autor: | Brandon-Luke L. Seagle, Wilberto Nieves-Neira, Roshan Karki, Shohreh Shahabi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Bevacizumab medicine.medical_treatment Angiogenesis Inhibitors Antineoplastic Agents Breast Neoplasms Antibodies Monoclonal Humanized chemistry.chemical_compound Internal medicine medicine Humans Pharmacology (medical) Protein Kinase Inhibitors Ovarian Neoplasms Pharmacology Biological Products Chemotherapy Taxane business.industry Cancer Trastuzumab medicine.disease Clinical trial Docetaxel Paclitaxel chemistry Chemotherapy Adjuvant Drug Therapy Combination Female Taxoids Ovarian cancer business medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 25:536-554 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/cad.0000000000000056 |
| Popis: | Taxane-based cytotoxic therapy is commonly prescribed for breast and ovarian cancers. Although these cancers are often sensitive to such therapy, clinical benefit and overall survival are limited owing to the development of chemoresistance and recurrence. Biologic agents that specifically target proteins of growth factor signaling pathways, which are hyperactivated in cancers, offer attractive targets for cancer therapeutics and may work synergistically with standard taxane-based chemotherapy to improve patient outcomes. We review clinical trials of biologic agents--angiogenic, tyrosine kinase, and antibody inhibitors--in combination with taxane-based therapy for ovarian and breast cancers. Many clinical trials have shown promising results. However, some biologic agents still need larger trials to assess safety and efficacy. As research into the heterogeneity and complexity of ovarian and breast cancers improves our understanding of the molecular pathways involved, there is no question that targeted therapies with biologic agents will expand the future array of available cancer therapeutics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|